Melanotan II is the one compound on this list where I think the honest research summary is closer to a warning than a research digest, and I'm not going to soften that to keep the tone consistent with everything else here.
What Melanotan II is
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone. Unlike more selective melanocortin compounds, it's non-selective, meaning it activates multiple melanocortin receptors (MC3, MC4, and MC5), which affect pigmentation but also appetite, sexual arousal, and blood pressure regulation, not just skin tanning.
What's actually been studied
- Melanoma case reports. Published case reports document melanoma occurring in people who used Melanotan II, along with documented rapid changes in existing moles and pigmented lesions after use, changes that can make it harder to visually detect skin cancer early (melanoma associated with the use of melanotan-II, PubMed).
- Other adverse event case reports. Separate case reports describe rhabdomyolysis (serious muscle breakdown) and renal infarction following Melanotan II injection.
- The causation question. A 2021 review discussing melanoma risk in Melanotan users noted that the increased risk could plausibly be explained by the sun-seeking behavior common among people using a tanning agent, meaning more UV exposure, rather than a direct carcinogenic effect of the peptide itself. That's a genuine, unresolved scientific question, not a reason to dismiss the case reports.
Where the evidence is thin
Most of the safety-relevant evidence here is case reports, not controlled trials, which is a real limitation for establishing causation. But case reports of melanoma, mole changes that complicate skin-cancer detection, rhabdomyolysis, and renal infarction are exactly the kind of serious adverse-event signal that case-report-level evidence is appropriate for flagging, even without a large controlled trial proving direct causation. The absence of controlled trials here isn't a reason for confidence, it's a reflection of the fact that this compound was never developed through a normal clinical trial pathway.
The regulatory picture
Melanotan II is not FDA-approved for any use, and its safety has not been established through the normal drug approval process. The Skin Cancer Foundation has specifically and publicly discouraged use of Melanotan II and other unapproved tanning agents. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
I try to stay even-handed across this list, but Melanotan II is the compound where I'd actively steer someone away rather than just flag thin evidence. The combination of a non-selective mechanism hitting receptors well beyond pigmentation, documented melanoma and mole-change case reports, and an actual public warning from a dermatology advocacy organization is a different risk profile than "understudied but plausible," which describes most of the rest of this list.
Sources
- Melanoma associated with the use of melanotan-II, PubMed
- The Skin Cancer Foundation Issues Warning Regarding Melanotan II
Sourcing for research
If you're sourcing peptides for laboratory research generally, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis. For this specific compound, I'd read the case reports above before anything else.